Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$10.93 and traded as high as C$11.67. Fennec Pharmaceuticals shares last traded at C$11.67, with a volume of 100 shares traded.
Fennec Pharmaceuticals Stock Up 2.7%
The stock has a market cap of C$231.03 million, a P/E ratio of -202.94 and a beta of 0.25. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The firm's fifty day moving average is C$11.06 and its 200 day moving average is C$9.52.
Insider Transactions at Fennec Pharmaceuticals
In other news, Director Rostislav Christov Raykov sold 16,667 shares of Fennec Pharmaceuticals stock in a transaction dated Friday, May 16th. The shares were sold at an average price of C$9.49, for a total transaction of C$158,203.16. Also, Senior Officer Robert Christopher Andrade bought 8,220 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were acquired at an average price of C$6.99 per share, for a total transaction of C$57,433.14. In the last 90 days, insiders have sold 39,913 shares of company stock worth $402,086. 16.20% of the stock is currently owned by company insiders.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Featured Articles
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
